In this episode of the DeviceTalks Weekly Podcast, we’ll talk with Intuitive Surgical’s Julian Nikolchev, senior vice president, corporate development and strategy, and Dr. Oliver Keown, director of Intuitive Ventures, about the new $100 million venture fund. How will the capital be invested? Where does Intuitive see the opportunity, and how does the program fit […]
Coloplast
The top 5 MassDevice stories of the week — November 6, 2020
The medical device industry continues to move along — with M&A deals made and earnings reported — even as many people focus on the U.S. presidential election. Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss the week’s “Newmarker’s Newsmakers” — as well as fictional monsters […]
Coloplast sees revenue growth accelerating in 2021, acquires Nine Continents Medical
Coloplast (CPH:COLO-B) announced today that it was able to boost its annual earnings even as the COVID-19 pandemic held down sales growth — with the Danish medical device giant expecting a stronger 2021. Also today, Coloplast announced that it has completed its acquisition of Nine Continents Medical, an early-stage company pioneering an implantable tibial nerve stimulation […]
DTW Podcast: New tools helping medtechs overcome COVID19 challenges
In this week’s DeviceTalks Weekly Podcast, senior executives from Avail Medsystems and AliveCor detail how their tools are helping medtechs remain in contact with both physicians and patients. In the keynote interview with Daniel Hawkins, CEO of Avail Medsystems, says the company’s Procedural Telemedicine system will allow medical device sales representatives to observe more procedures […]
The top 5 MassDevice stories of the week — October 2, 2020
Major medtech companies are making tuck-in acquisitions and investments as they seek innovations to help them grow out of the COVID-19 pandemic and resulting recession. That was a major takeaway from our top stories on MassDevice over the past week. Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom […]
Coloplast invests $4M in Francis Medical
Urological cancer treatment developer Francis Medical announced today that it received a $4 million equity investment from Coloplast (CPH:COLO-B). Minneapolis-based Francis Medical develops ablation technology designed to apply thermal energy stored in sterile water vapor to deliver targeted treatments to the cancerous tissue in a transurethral procedure, according to a news release. The procedure potentially minimizes […]
Report: More women harmed by medical devices than men
A new investigation of FDA adverse event data has revealed that more women are harmed by medical devices than men. The report published by the International Consortium of Investigative Journalists (ICIJ) shows that among 340,000 people whom the FDA listed as having been injured by a medical device, women made up 67%, compared with men […]
Coloplast recalls stents due to package sterility issue
Coloplast (CPH:COLO-B) recalled nine total batches of its Biosoft Duo double loop ureteral stent kit and Vortek double loop ureteral stent kit due to a packaging anomaly. Humlebaek, Denmark–based Coloplast issued an urgent field safety notice out of Germany earlier this month to warn users of the packaging issue and instruct them to review stock and […]
Coloplast to keep interventional urology business
Coloplast (CPH:COLO-B) officials have decided to keep the company’s interventional urology business — about five months after confirming it was the subject of a strategic review. “After completing a thorough review, we have firmly concluded that the interventional urology business is core to our mission, and that retaining the business is the right decision to […]
Coloplast could sell its interventional urology business
Coloplast (CPH:COLO-B) recently confirmed that it is conducting an unconditional strategic review of its interventional urology division. That’s corporate speak for potentially selling it. The June 4 announcement came amid rumors of a potential sale. A Coloplast spokesperson had no further comments when reached by MassDevice. Coloplast’s interventional urology business grew 6% during the fiscal […]
FDA’s pelvic mesh ban spooks investors
The FDA’s ban on U.S. sales of pelvic mesh products for pelvic organ prolapse may have spooked investors, but should only have a minimal effect on the books at Boston Scientific (NYSE:BSX) and Coloplast (CPH:COLO-B) – the only companies still selling mesh for prolapse in the U.S. – according to analysts and the company. Yesterday the […]
